General
Hyrimoz (Adalimumab)
Virtual visit

Hyrimoz (Adalimumab)

With our quick and easy online prescription process, you can manage your health effortlessly — whether you need a first-time prescription for Hyrimoz (Adalimumab) or a refill of an existing one.

Licensed providers in all 50 states

Expert-guided, evidence-based treatments

Skip the trip to the doctor's office

Visit options

Costs shown are for the visit only. You'll pay for medication at your preferred pharmacy.

Video Visit

$25

Est. or $100 w/o insurance

Chat Visit

$30

w/o insurance

Most insurance accepted

Board-certified

No hidden fees

Available nationwide

What is Hyrimoz (Adalimumab)?

Hyrimoz is an FDA-approved biosimilar to Humira (adalimumab), a biologic medication that neutralizes TNF-alpha—the inflammatory protein central to conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As a biosimilar, Hyrimoz has been rigorously evaluated and confirmed to have no clinically meaningful differences from reference adalimumab in safety, purity, and potency. It provides the same mechanism of action and clinical benefit as Humira, often with improved accessibility. It's administered as a subcutaneous injection every one to two weeks depending on the condition.

TNF-alpha neutralization

Binds to and blocks tumor necrosis factor-alpha, the key inflammatory cytokine driving joint destruction, intestinal inflammation, and skin plaques in multiple immune-mediated conditions—interrupting the inflammatory cascade at its source.

Regulatory-confirmed biosimilar equivalence

Hyrimoz has undergone the FDA's rigorous biosimilar approval pathway—including analytical, clinical pharmacology, and safety data—confirming it is highly similar to Humira with no clinically meaningful differences.

Disease-modifying access

Provides the same disease-modifying biological therapy as reference adalimumab—slowing structural damage in arthritis, inducing and maintaining remission in IBD, and clearing skin plaques in psoriasis—with improved access as a biosimilar option.

Virtual visit with clinician

Ongoing support, always available.

You’ll be supported by experienced clinicians who care for a wide range of health needs, from everyday concerns to more complex conditions.

Our clinicians track your progress over time and adjust your care as needed. If medication is prescribed, we’ll manage dosing and monitor for side effects. If lab testing is recommended, we review results and refine your plan accordingly. You’re never left to navigate care on your own.

All your care in one place. That’s the General Medicine difference.

We help you understand your options, connect you to the right clinicians, manage prescriptions, coordinate any needed evaluations, and keep an eye on your overall health along the way. It’s comprehensive care that looks at the full picture — your goals, your history, your lifestyle — and makes it simple to move forward with confidence.

Your care plan
Clinician

What our customers have to say

“I feel like I’m finally on the right path to improving my health with the right support now! It’s so refreshing and reassuring.”

Emerald

“My experience with General Medicine was amazing. The understanding and care that was taken to figure out what is exactly going on with me. I feel like a weight has been lifted off of me.”

Kaylee

“I couldn’t be happier with my experience with General Medicine! They are fast, responsive, kind and knowledgeable. It is much easier, more affordable and faster.”

Nika

Get the care you need, without the wait.

Frequently Asked Questions

What is Hyrimoz and how does it relate to Humira?

Hyrimoz is an FDA-approved biosimilar to Humira (adalimumab) — confirmed through rigorous regulatory review to have no clinically meaningful differences in safety, purity, or potency from the reference biologic.

Is it safe to switch from Humira to Hyrimoz?

Biosimilar approval includes assessment of switching safety. Many patients transition from Humira to biosimilars including Hyrimoz without loss of efficacy or increased adverse effects — switches are often recommended by clinicians and insurance plans.

What conditions does Hyrimoz treat?

As an adalimumab biosimilar, Hyrimoz carries the same approvals as Humira — including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and others.

What side effects might I experience?

Injection site reactions, upper respiratory infections, and headache are most common. The most serious risk — as with all adalimumab products — is serious infection including tuberculosis reactivation, screened for before starting.

Why might my clinician or insurance recommend Hyrimoz over Humira?

Biosimilars typically offer equivalent therapeutic benefit at lower cost — expanding patient access to biologic therapy. Insurance formularies increasingly prefer biosimilars, and clinicians support these transitions when appropriate for established patients.
Logo

© 2026 Path Healthcare Systems Corp.